Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Prolonged administration of oral etoposide in non-small-cell lung cancer: a phase II trial.

Waits TM, Johnson DH, Hainsworth JD, Hande KR, Thomas M, Greco FA.

J Clin Oncol. 1992 Feb;10(2):292-6.

PMID:
1310104
2.

Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial.

Johnson DH, Greco FA, Strupp J, Hande KR, Hainsworth JD.

J Clin Oncol. 1990 Oct;8(10):1613-7.

PMID:
2170589
3.

Pharmacodynamics of prolonged oral etoposide in patients with advanced non-small-cell lung cancer.

Miller AA, Tolley EA, Niell HB, Griffin JP, Mauer AM.

J Clin Oncol. 1993 Jun;11(6):1179-88.

PMID:
8388920
4.

Carboplatin plus oral etoposide in the management of advanced, non-small cell lung cancer: preliminary results of a Vanderbilt trial.

Johnson DH, DeVore R, Greco FA, Walls J, Thomas M, Hande KR, Hainsworth JD.

Semin Oncol. 1992 Feb;19(1 Suppl 2):50-6.

PMID:
1329223
5.

Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide.

Minami H, Ando Y, Sakai S, Shimokata K.

J Clin Oncol. 1995 Jan;13(1):191-9.

PMID:
7799020
6.
7.
8.

Phase II trial of daily oral etoposide in patients with advanced non-small cell lung cancer.

Saxman S, Loehrer PJ Sr, Logie K, Stephens D, Workman F, Scullin D, Einhorn LH, Ansari R.

Invest New Drugs. 1991 Aug;9(3):253-6.

PMID:
1664423
9.

Fractionated doses of oral etoposide in the treatment of patients with aids-related kaposi sarcoma: a clinical and pharmacologic study to improve therapeutic index.

Sprinz E, Caldas AP, Mans DR, Cancela A, DiLeone L, Dalla Costa T, Schwartsmann G.

Am J Clin Oncol. 2001 Apr;24(2):177-84.

PMID:
11319295
10.

Superiority of sequential versus concurrent administration of paclitaxel with etoposide in advanced non-small cell lung cancer: comparison of two Phase II trials.

Felip E, Massuti B, Camps C, Benito D, Isla D, González-Larriba JL, López-Cabrerizo MP, Salamanca O, Puerto-Pica J, Moyano A, Baselga J, Rosell R.

Clin Cancer Res. 1998 Nov;4(11):2723-8.

11.

A phase II trial of cisplatin and prolonged administration of oral etoposide in extensive-stage small cell lung cancer.

Murphy PB, Hainsworth JD, Greco FA, Hande KR, DeVore RF, Johnson DH.

Cancer. 1992 Jan 15;69(2):370-5.

12.

Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study.

Wolff AC, Ettinger DS, Neuberg D, Comis RL, Ruckdeschel JC, Bonomi PD, Johnson DH.

J Clin Oncol. 1995 Jul;13(7):1615-22.

PMID:
7602350
13.

Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.

Masuda N, Fukuoka M, Kudoh S, Matsui K, Kusunoki Y, Takada M, Nakagawa K, Hirashima T, Tsukada H, Yana T, et al.

J Clin Oncol. 1994 Sep;12(9):1833-41.

PMID:
7521905
14.

Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: a phase I/II study.

Thompson DS, Hainsworth JD, Hande KR, Holzmer MC, Greco FA.

J Clin Oncol. 1993 Jul;11(7):1322-8.

PMID:
8315429
15.

Chronic oral etoposide in non-small cell lung carcinoma.

Estapé J, Palombo H, Sánchez-Lloret J, Agustí C, Grau JJ, Daniels M, Viñolas N, Solá C, Biete A, Ramirez J.

Eur J Cancer. 1992;28A(4-5):835-7.

PMID:
1326308
16.
17.

Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.

Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, Engstrom PF, Litwin S, Ozols RF.

J Clin Oncol. 1995 Aug;13(8):1860-70.

PMID:
7543559
18.

A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study.

Graziano SL, Valone FH, Herndon JE 2nd, Crawford J, Richards F 2nd, Rege VB, Clamon G, Green MR.

Lung Cancer. 1996 Jun;14(2-3):315-29.

PMID:
8794413
19.

Phase I/II study of carboplatin and oral etoposide with granulocyte-colony stimulating factor in advanced nonsmall cell lung cancer.

Frasci G, Perillo G, Comella G, Comella P, Polverino M, Menzella G, Persico G.

Cancer. 1995 Apr 1;75(7):1578-85.

20.

Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.

Chabot GG, Armand JP, Terret C, de Forni M, Abigerges D, Winograd B, Igwemezie L, Schacter L, Kaul S, Ropers J, Bonnay M.

J Clin Oncol. 1996 Jul;14(7):2020-30.

PMID:
8683232

Supplemental Content

Support Center